Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 29 | 2023 | 15694 | 1.640 |
Why?
|
| Potentially Inappropriate Medication List | 2 | 2019 | 12 | 1.330 |
Why?
|
| Geriatrics | 3 | 2019 | 98 | 0.940 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 14289 | 0.710 |
Why?
|
| Geriatric Assessment | 3 | 2018 | 275 | 0.650 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 50 | 0.630 |
Why?
|
| Receptors, Estrogen | 8 | 2023 | 2086 | 0.610 |
Why?
|
| Choice Behavior | 1 | 2019 | 226 | 0.590 |
Why?
|
| Pyridines | 6 | 2023 | 1244 | 0.550 |
Why?
|
| Emotions | 1 | 2019 | 562 | 0.510 |
Why?
|
| Piperazines | 6 | 2023 | 2101 | 0.480 |
Why?
|
| Delirium | 1 | 2016 | 207 | 0.460 |
Why?
|
| Cognition | 2 | 2016 | 968 | 0.450 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 3578 | 0.440 |
Why?
|
| Plasmacytoma | 1 | 2013 | 111 | 0.420 |
Why?
|
| Cancer Survivors | 1 | 2019 | 650 | 0.420 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2022 | 3890 | 0.410 |
Why?
|
| Dementia | 1 | 2016 | 453 | 0.390 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2020 | 799 | 0.390 |
Why?
|
| Organ Transplantation | 1 | 2013 | 191 | 0.380 |
Why?
|
| Aged | 26 | 2023 | 70117 | 0.370 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 366 | 0.370 |
Why?
|
| Cognition Disorders | 1 | 2016 | 786 | 0.370 |
Why?
|
| Disease Management | 1 | 2015 | 1052 | 0.360 |
Why?
|
| Medical Oncology | 5 | 2020 | 1423 | 0.350 |
Why?
|
| Medicare | 3 | 2019 | 860 | 0.350 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 552 | 0.340 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 489 | 0.320 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 29902 | 0.310 |
Why?
|
| Female | 35 | 2023 | 141928 | 0.310 |
Why?
|
| Comorbidity | 4 | 2021 | 2352 | 0.300 |
Why?
|
| Receptor, ErbB-2 | 9 | 2023 | 2518 | 0.300 |
Why?
|
| SEER Program | 3 | 2020 | 1000 | 0.290 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2020 | 393 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 15862 | 0.270 |
Why?
|
| Lymphoma | 1 | 2013 | 1467 | 0.240 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 598 | 0.240 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 1429 | 0.240 |
Why?
|
| Humans | 39 | 2023 | 261506 | 0.230 |
Why?
|
| Aminopyridines | 2 | 2023 | 212 | 0.220 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 13658 | 0.220 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2023 | 1215 | 0.210 |
Why?
|
| Receptors, Androgen | 2 | 2017 | 878 | 0.200 |
Why?
|
| Aging | 2 | 2020 | 1582 | 0.190 |
Why?
|
| Maytansine | 1 | 2020 | 38 | 0.190 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2021 | 116 | 0.180 |
Why?
|
| Androstadienes | 1 | 2021 | 165 | 0.180 |
Why?
|
| Neoplasms | 5 | 2018 | 15193 | 0.180 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2016 | 36 | 0.170 |
Why?
|
| Purines | 1 | 2021 | 273 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2021 | 556 | 0.170 |
Why?
|
| Everolimus | 1 | 2021 | 415 | 0.170 |
Why?
|
| United States | 4 | 2020 | 15433 | 0.160 |
Why?
|
| Age Factors | 5 | 2020 | 5377 | 0.160 |
Why?
|
| Clinical Protocols | 1 | 2020 | 467 | 0.160 |
Why?
|
| Polypharmacy | 1 | 2018 | 57 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 292 | 0.160 |
Why?
|
| Immunoconjugates | 1 | 2020 | 279 | 0.150 |
Why?
|
| Fluoxymesterone | 1 | 2016 | 9 | 0.150 |
Why?
|
| Hyponatremia | 1 | 2018 | 82 | 0.150 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2017 | 112 | 0.140 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 115 | 0.140 |
Why?
|
| Retinoblastoma Protein | 1 | 2017 | 335 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2023 | 12873 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 621 | 0.130 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 4988 | 0.130 |
Why?
|
| Life Expectancy | 1 | 2015 | 129 | 0.130 |
Why?
|
| Pharmacology, Clinical | 1 | 2014 | 10 | 0.130 |
Why?
|
| Cyclin E | 1 | 2017 | 267 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 4757 | 0.130 |
Why?
|
| Fractures, Bone | 1 | 2017 | 291 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 6550 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 588 | 0.120 |
Why?
|
| Decision Making | 1 | 2021 | 1287 | 0.120 |
Why?
|
| Middle Aged | 15 | 2023 | 86204 | 0.120 |
Why?
|
| Research | 1 | 2016 | 415 | 0.120 |
Why?
|
| Retrospective Studies | 7 | 2023 | 37905 | 0.120 |
Why?
|
| Hematology | 1 | 2014 | 104 | 0.110 |
Why?
|
| Risk Factors | 4 | 2020 | 17523 | 0.110 |
Why?
|
| Male | 10 | 2023 | 123000 | 0.110 |
Why?
|
| Patient Preference | 1 | 2015 | 218 | 0.110 |
Why?
|
| Informed Consent | 1 | 2016 | 419 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4320 | 0.110 |
Why?
|
| Quality of Life | 3 | 2023 | 4532 | 0.110 |
Why?
|
| Sex Factors | 1 | 2018 | 2139 | 0.110 |
Why?
|
| Social Support | 1 | 2015 | 560 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 14889 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 1121 | 0.110 |
Why?
|
| Plasma Cells | 1 | 2013 | 192 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 4314 | 0.100 |
Why?
|
| Prevalence | 2 | 2016 | 3260 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 973 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 333 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 840 | 0.100 |
Why?
|
| Adult | 13 | 2021 | 77950 | 0.100 |
Why?
|
| DNA Repair | 1 | 2019 | 1872 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 3001 | 0.100 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 390 | 0.100 |
Why?
|
| Mass Screening | 1 | 2019 | 1509 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 5178 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2017 | 1678 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 1085 | 0.090 |
Why?
|
| Hospitalization | 1 | 2019 | 2083 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.090 |
Why?
|
| Paclitaxel | 3 | 2023 | 1996 | 0.090 |
Why?
|
| Anthracyclines | 2 | 2023 | 331 | 0.090 |
Why?
|
| Curriculum | 1 | 2014 | 860 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 3719 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2021 | 129 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2021 | 198 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 1914 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 10001 | 0.080 |
Why?
|
| Terminal Care | 1 | 2012 | 447 | 0.080 |
Why?
|
| Estrogen Receptor alpha | 2 | 2023 | 701 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5687 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8865 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2018 | 9180 | 0.070 |
Why?
|
| Recurrence | 1 | 2013 | 4758 | 0.060 |
Why?
|
| Mastectomy | 2 | 2020 | 1534 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 4975 | 0.050 |
Why?
|
| Aurora Kinase A | 1 | 2023 | 202 | 0.050 |
Why?
|
| Palliative Care | 1 | 2012 | 2037 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 305 | 0.050 |
Why?
|
| Folate Receptor 1 | 1 | 2020 | 62 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2020 | 205 | 0.040 |
Why?
|
| Gene Expression | 2 | 2017 | 3570 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2330 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 175 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2020 | 32848 | 0.040 |
Why?
|
| Oncologists | 1 | 2019 | 134 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 249 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 12926 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 1178 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1026 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 756 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2017 | 382 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2017 | 652 | 0.030 |
Why?
|
| Advanced Practice Nursing | 1 | 2014 | 14 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1392 | 0.030 |
Why?
|
| Oncology Nursing | 1 | 2014 | 51 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1945 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 3472 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 485 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1313 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 233 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 2218 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 915 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 1544 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 14551 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1271 | 0.030 |
Why?
|
| Adolescent | 1 | 2013 | 31252 | 0.030 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 10331 | 0.030 |
Why?
|
| Mutation | 2 | 2022 | 15179 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2017 | 2084 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2012 | 303 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 4298 | 0.020 |
Why?
|
| Autophagy | 1 | 2017 | 927 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 4938 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 521 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 21445 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 6682 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2017 | 4307 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 4804 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2012 | 1163 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 829 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 671 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 5673 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 2594 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 7548 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 6869 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 5159 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 6311 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6207 | 0.020 |
Why?
|
| Brain | 1 | 2020 | 4113 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 5112 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 10035 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 11965 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 34495 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 21713 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 59536 | 0.010 |
Why?
|